Pharmaceutical sponsor
Nanjing Leads Biolabs Co.,Ltd Clinical Trials
Studies where Nanjing Leads Biolabs Co.,Ltd is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 13Advanced Melanoma
A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy or combination with toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and…
- Trial name
- NCT07099430
- Testing
- LBL-024 for Injection, Toripalimab Injection
- Where
- 16 sites in China
- Volunteers
- 280 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Systemic Lupus Erythematosus
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
A Double-blind, Randomized, Placebo-controlled, Dose-escalation Phase I Study to Assess the Safety and PK/PD of LBL-047 Subcutaneous Injection in Healthy Adults and Patients with Systemic Lupus Erythematosus.
- Trial name
- NCT07323173
- Testing
- LBL-047 for Injection
- Where
- 12 sites in China
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumour
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
- Trial name
- NCT07111546
- Testing
- LBL-024 for Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection
- Where
- 16 sites in China
- Volunteers
- 140 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Advanced Extrapulmonary Neuroendocrine Carcinoma
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or…
- Trial name
- NCT07720193
- Testing
- LBL-024 for Injection, Etoposide injection, Cisplatin injection
- Where
- 36 sites in China
- Volunteers
- 280 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Metastatic Colorectal Carcinoma
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate…
- Trial name
- NCT07791758
- Testing
- LBL-024 for Injection, Bevacizumab injection, Oxaliplatin injection
- Where
- 10 sites in China
- Volunteers
- 369 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Relapsed/Refractory Multiple Myeloma
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.
- Trial name
- NCT06049290
- Testing
- LBL-034 for Injection
- Where
- 21 sites in China
- Volunteers
- 342 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumour
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
- Trial name
- NCT06783647
- Testing
- LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection
- Where
- 24 sites in China
- Volunteers
- 250 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Ovarian Cancer
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
This study is an open-label, multicenter Phase Ib/II clinical trial of LBL-024 in combination with other drugs for the treatment of patients with platinum-resistant ovarian cancer (OC), aiming to evaluate the efficacy and safety…
- Trial name
- NCT07042802
- Testing
- LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection
- Where
- 13 sites in China
- Volunteers
- 180 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumor
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors
- Trial name
- NCT05170958
- Testing
- LBL-024 for Injection
- Where
- 49 sites in China
- Volunteers
- 396 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumour
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
- Trial name
- NCT07331155
- Testing
- LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd